Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 912345...Last »

Tempest Therapeutics Leaps into IDO Development

Versant Ventures spinoff company Tempest Therapeutics secured $70 million in a Series B funding to advance the company’s immunotherapy pipeline.

Read More »

FDA working on a ‘dozen’ policies to boost copycat biotech drugs

The U.S. Food AND Drug Administration is working on around a dozen actions to boost use of cheaper versions of expensive biotech medicines, the head of the agency Scott Gottlieb said.

Read More »

Outcome Health And The Colorectal Cancer Alliance Announce Campaign To Support Patient Education

Outcome Health, a technology company that provides health education at the moment of care to improve patient outcomes, announced a partnership with the Colorectal Cancer Alliance to make patients aware of the signs and symptoms of colorectal cancer.

Read More »

Roche shares drop after deaths of patients taking Hemlibra

Roche’s shares dropped after the Swiss drugmaker told U.S.-based hemophilia advocacy groups that five patients treated with its medicine Hemlibra had died, while maintaining that the therapy was not the cause of the deaths.

Read More »

Tokyo court rejects Shire claim against Roche hemophilia drug

A Tokyo court ruled that Shire’s claim against Swiss drugmaker Roche’s new Hemlibra hemophilia medicine should be dismissed, Roche’s Japanese subsidiary Chugai said.

Read More »

AnaptysBio’s Mid-Stage Peanut Allergy Data Indicates Positive Results

Shares of AnaptysBio climbed after the company released positive interim data for its experimental peanut allergy treatment.

Read More »

FDA Accepts Bristol-Myers Combo Application

The U.S. Food and Drug Administration accepted Bristol-Myers Squibb’s supplemental Biologics License Application for Opdivo (nivolumab) with Yervoy (ipilimumab) for a type of colorectal cancer.

Read More »

Omnicom Health Group acquires Elsevier’s Pharma Communications business in Japan

Omnicom Health Group announced that it has entered into a definitive agreement to acquire the Pharma Communications business in Japan of Elsevier, part of RELX Group.

Read More »

After Spurning Pfizer, GlaxoSmithKline Cuts $13 Billion Deal with Novartis

GlaxoSmithKline opted to invest in its own consumer unit by acquiring the stake controlled by Swiss pharma giant Novartis.

Read More »

Clot-Busting Stroke Medicine: Mired in Controversy

An ischemic stroke occurs as a result of an obstruction within a blood vessel supplying blood to the brain and accounts for about 87 percent of all strokes, according to the American Stroke Association. A common treatment used to break up the clots and prevent brain damage has become mired in controversy.

Read More »

Esperion’s drug clears study as add-on cholesterol treatment

Esperion Therapeutics’ experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients who were already on another treatment to lower the risk of artery-clogging heart disease.

Read More »

FDA approves Toujeo Max SoloStar

The U.S. Food and Drug Administration approved Sanofi’s Toujeo (insulin glargine 300 Units/mL) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the market.

Read More »

U.S. jury orders AbbVie to pay $3+ million

A U.S. jury ordered AbbVie Inc. to pay more than $3 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel.

Read More »

Genentech’s Late-Stage Trial Data Shows Combination of Tecentriq and Avastin Helps NSCLC Patients Live Longer

Genentech Inc. is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.

Read More »

Ablynx Lupus Drug Fails Again in Mid-Stage Trial

Ablynx’s anti-IL-6R nanobody vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.

Read More »

ImmunoGen Reports Positive Ovarian Cancer Data

ImmunoGen released positive efficacy and tolerability data from its FORWARD II trial of mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer.

Read More »

Protagonist Therapeutics Discontinues Phase IIb Ulcerative Colitis Study

Protagonist Therapeutics Inc. discontinued a Phase IIb study for the experimental ulcerative colitis treatment PTG-100 following a review from an Independent Data Monitoring Committee (DMC).

Read More »

Biohaven plunges as investors pit migraine data against Allergan’s drug

Biohaven Pharmaceutical Holding said the company’s treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan’s rival treatment.

Read More »

Brite Media Group Acquires Mesmerize Marketing

Brite Media Group, a leading out-of-home advertising company, announced the acquisition of Mesmerize Marketing.

Read More »

Israel to launch Big Data health project

Israel will invest nearly 1 billion shekels ($287 million) in a project to make data about the state of health of its population available to researchers and private companies, Prime Minister Benjamin Netanyahu said.

Read More »

Page 2 of 912345...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom